Skip to content
EN
brief us →

Purdue Pharma L.P.: owners, OxyContin cases and bankruptcy

Research data: Purdue Pharma L.P.: owners, OxyContin cases and bankruptcy

This dataset contains the same public evidence as the dossier: participants, relationships, events, assertions and sources. Qualifications, replies and known outcomes are retained in JSON, JSONL and CSV. The scope and method explain which original records were accepted; this is not a copy of the original archive.

published
02 nov 2026
records as of
22 oct 2026
entities
205
sources
115
cite entities.csv

Downloads

As of 22 October 2026. 731 claims · 205 parties · 410 connections · 97 events · 115 sources

Scope and method

Covers Purdue Pharma L.P., its general partner Purdue Pharma Inc., the other Chapter 11 debtors, the ownership chain up to the Sackler family trusts, directors and officers, the independent associated companies insofar as they connect to Purdue, consultants and distributors, and the courts' and regulators' actions, from the founding of the Purdue Frederick Company in 1892 to records retrieved on 22 October 2026. It relies on a fixed set of retrieved documents; documents cited in them but not retrieved, including several pleadings, plea schedules and settlement exhibits, were not read.

Every statement and relationship found in the documents reviewed was read and given a recorded decision, and each public claim was compared with the exact passage of its source document. For each allegation, all retained document text was searched for responses and outcomes, which are kept beside the claim. Sources other than official records of federal and state courts, the Department of Justice, state attorneys general and agencies, local governments, the U.S. House of Representatives, the SEC, the FEC, HHS-OIG, WIPO and official company and charity registers are identified by category only. Personal details such as ages, birth dates, nationality and home addresses are omitted, as are personal matters of relatives that have no connection with Purdue. The review was carried out by an AI editor without independent human review.

chronology

  1. John Purdue Gray and George Frederick Bingham found the Purdue Frederick Company c-hist-origins
  2. Arthur, Mortimer and Raymond Sackler buy the Purdue Frederick Company c-hist-origins
  3. Richard, Jonathan and Kathe Sackler and Ilene Sackler Lefcourt begin their terms on the board of Purdue Pharma Inc. c-board-rsackler-director c-board-jsackler-director c-board-kathe-director c-board-ilene-director
  4. Purdue Pharma L.P. is formed as a Delaware limited partnership c-id-formation
  5. Ten Sackler family members are recorded as directors of Napp Pharmaceutical Group Limited from this date c-iac-napp-group-family
  6. The FDA approves OxyContin for marketing in the United States c-bus-irs-oxycontin-sales c-bus-principal-opioids
  7. Purdue launches OxyContin c-bus-principal-opioids
  8. FDA requires Purdue to drop a low-addiction-risk claim from the OxyContin label and add its strongest warning c-plea07-fda-2001-label
  9. The Purdue Pharma Inc. Political Action Committee is registered with the FEC c-bus-pac-fec
  10. Florida settles its investigation into Purdue for $500,000 c-lit-settle-florida-2002
  11. Purdue Pharma L.P. and Purdue Pharma Inc. are registered to do business in Florida c-id-florida-cards c-id-florida-2003
  12. West Virginia settles its suit against Purdue for $10 million c-lit-settle-west-virginia-2004
  13. The Purdue Pharma Company partnership is terminated; OxyContin sales are booked by Purdue Pharma L.P. c-hist-purdue-pharma-company c-hist-pfc-owner-2004
  14. Mississippi settles its investigation into Purdue for $250,000 c-lit-settle-mississippi-2006
  15. Purdue companies and Endo settle the OxyContin patent litigation with a consent judgment and licence c-bus-endo-2006 c-bus-endo-patents
  16. Twenty-six states and the District of Columbia settle with Purdue for $19.5 million under consent judgments c-plea07-state-settlement c-plea07-combined-total
  17. The Purdue Frederick Company pleads guilty to felony misbranding; three of its current and former executives plead guilty to misdemeanours c-plea07-pfc-plea c-plea07-executive-pleas
  18. David Sackler emails Richard and Jonathan Sackler and an adviser about the family's liability, as the District Court recounted c-fam-2007-email-counsel
  19. Jonathan, Kathe and Mortimer D.A. Sackler end their officer titles at Purdue Pharma Inc. and Purdue Pharma L.P. c-board-family-officers-2007
  20. John Stewart becomes chief executive officer of Purdue Pharma L.P. and Purdue Pharma Inc. c-exec-stewart-ceo
  21. Judge James P. Jones approves The Purdue Frederick Company's plea agreement c-plea07-plea-approval
  22. A family financial adviser warns Jonathan Sackler of uncapped liabilities, according to the District Court c-fam-2007-advisor-memo
  23. Around 1 January, Rhodes Tech leaves Purdue Pharma L.P. for another Sackler ownership chain, the debtors state c-bus-rhodes-history
  24. Mortimer D.A. Sackler writes that the family is too exposed to pharmaceuticals, as Connecticut's complaint quotes c-fam-mda-2008-email
  25. Peter Boer becomes a director of Purdue Pharma Inc. c-board-boer
  26. Purdue Pharmaceutical Products L.P. and Infinity Pharmaceuticals form a strategic alliance c-bus-infinity-alliance c-bus-infinity-investment
  27. Administrative law judge upholds the 15-year HHS-OIG exclusions of the three former Purdue Frederick executives c-plea07-executive-exclusions
  28. Purdue Pharma L.P. buys Series E preferred stock and warrants of Novelos Therapeutics for $10 million c-bus-novelos-purchase
  29. WIPO panel orders four OxyContin domain names transferred to Purdue Pharma L.P. c-bus-oxycontin-trademarks
  30. Monitoring period under Purdue Pharma L.P.'s 2007 Corporate Integrity Agreement expires c-plea07-cia
  31. Purdue executives sign the consulting contract for the OxyContin sales assessment later called E2E c-cons-addendum-contract c-cons-consulting-company-identity
  32. Mark Timney becomes chief executive officer of Purdue Pharma L.P. and Purdue Pharma Inc. c-exec-timney-ceo
  33. KBR announces a contract to build Purdue Pharma Manufacturing L.P.'s Durham plant c-bus-durham-kbr
  34. Purdue agrees to pay Kentucky $24 million to settle the state’s 2007 suit c-lit-settle-kentucky
  35. New York ends its investigation of Purdue Pharma L.P. by an assurance of discontinuance and a $75,000 penalty c-lit-settle-new-york-2015
  36. Celldex Therapeutics completes its merger with Kolltan Pharmaceuticals c-dist-celldex-kolltan
  37. Federal opioid cases against Purdue and other defendants are sent to MDL-2804 in Ohio c-lit-second-wave-mdl
  38. Cash distributions to the Sackler families end and Purdue Pharma L.P. lends $313 million to its parent, the debtors state c-dist-cessation
  39. Craig Landau is appointed President and CEO of Purdue Pharma L.P. as Mark Timney leaves c-board-landau-network-board c-exec-landau-ceo c-exec-timney-ceo
  40. At Craig Landau's direction Purdue stops using sales representatives to promote opioids to prescribers c-exec-landau-promotion-stop
  41. Companies House records seven family directors leaving Napp Pharmaceutical Group and five leaving Napp Holdings c-iac-napp-group-family c-iac-napp-holdings-family
  42. Purdue Pharma L.P. names Steve Miller board chairman and Marc Kesselman general counsel c-board-miller-appointed c-exec-kesselman-appointed
  43. Richard Sackler leaves the board of Purdue Pharma Inc. c-board-rsackler-director
  44. The New York Attorney General sues Purdue Pharma over the marketing of OxyContin c-lit-new-york
  45. Purdue entities agree to pay Assertio $62 million to settle a patent case c-bus-assertio-2018
  46. Cornice Fiduciary Management LLC succeeds Leslie J. Schreyer as trustee of a 1989 trust for the issue of Jonathan D. Sackler c-own-cornice-succession
  47. Two Mundipharma managers accept plea bargains in an Italian corruption case, according to a press report c-iac-mundipharma-italy-case
  48. Mortimer D.A. Sackler, the last family director, leaves the board of Purdue Pharma Inc. c-board-mdas-director c-board-sackler-exit
  49. The FDA's approval of Adlon Therapeutics' Adhansia XR is reported c-bus-adlon-adhansia
  50. Purdue settles Oklahoma’s opioid suit for $270 million c-lit-settle-oklahoma-2019 c-lit-oklahoma-family-contribution
  51. New York amends its complaint to add claims against eight family members and Sackler entities c-lit-new-york
  52. Rhodes Pharma and Rhodes Tech are contributed to Purdue Pharma L.P., the debtors state c-bus-rhodes-history
  53. Connecticut amends its complaint against Purdue, eight family members, five directors, John Stewart and Mark Timney c-lit-connecticut
  54. Purdue Pharma Inc.'s shareholders create a Transaction Committee closed to Sackler family members c-board-transaction-committee
  55. Maryland’s Consumer Protection Division opens an administrative proceeding against Purdue c-lit-maryland
  56. John S. Dubel and Michael Cola take At-Large Director seats on the board of Purdue Pharma Inc. c-board-2025-directors
  57. The Transaction Committee is renamed the Special Committee and given authority over litigation with the Sackler Families c-board-special-committee-2019
  58. A New York court seeks documents from Banela Corporation in the British Virgin Islands c-lit-ny-letter-rogatory
  59. Purdue Pharma L.P. and 23 affiliates file for Chapter 11; no Sackler family member or family entity files c-ch11-petition c-ch11-sacklers-not-debtors
  60. The debtors' ownership statement names PRA as sole owner of Purdue Pharma L.P. and Banela, Linarite and Perthlite as owners of Purdue Pharma Inc. c-own-pra-pplp c-own-ppi-shareholders
  61. Notice of the bankruptcy stay is filed in the Massachusetts case c-lit-massachusetts
  62. The U.S. Trustee appoints the Official Committee of Unsecured Creditors in the Purdue case c-ch11-ucc
  63. Cedar Cliff Fiduciary Management Inc. is first registered as a Wyoming corporation c-own-cedar-cliff-registry
  64. The Bankruptcy Court halts litigation against Purdue and non-debtor related parties, including Sackler family members c-ch11-injunction
  65. Purdue Pharma Inc.'s shareholders delegate the power to appoint and remove the chairman and at-large directors to its general counsel c-board-letter-agreement
  66. The Bankruptcy Court's preliminary injunction order protects the debtors and the named non-debtor Related Parties c-ch11-injunction c-rel-related-parties
  67. The debtors file the 1A Report: about $10.347 billion of net cash distributions to or for Sackler family members and entities, 2008–2019 c-dist-1a-report
  68. The Ontario Superior Court of Justice extends the recognised stay to the Related Parties in Canada c-ch11-canada-recognition
  69. The Bankruptcy Court appoints Layn Phillips and Kenneth Feinberg as co-mediators c-ch11-mediation
  70. The debtors file the 1B Report on non-cash transfers and dealings with Sackler entities c-dist-1b-bates-white
  71. Jonathan Sackler dies, according to a court filing cited in the press; his estate later signs the 2020 settlement c-fam-jonathan-death
  72. The extended deadline for proofs of claim against the Purdue debtors expires c-ch11-bar-date
  73. The United States files a civil proof of claim in Purdue's bankruptcy estimating single damages of $2.8 billion or more c-plea20-proof-of-claim
  74. The Bankruptcy Court approves the sale of Rhodes Tech's Coventry plant to Noramco Coventry LLC c-bus-coventry-sale
  75. DOJ announces Purdue Pharma L.P.'s agreement to plead guilty and a separate $225 million civil settlement with five Sackler family members c-plea20-global-resolution c-plea20-sackler-settlement
  76. Information filed; Purdue Pharma L.P. pleads guilty to three federal conspiracy counts c-plea20-information c-plea20-plea
  77. The debtors file their first plan, built on the Sackler families' $4.275 billion contribution c-ch11-sackler-agreement c-ch11-plan-path
  78. Judge Drain confirms the Twelfth Amended plan, including releases of claims against the Sackler family c-ch11-plan-path
  79. The District Court vacates the confirmation order, holding nonconsensual third-party releases unauthorised c-rel-dc-holding
  80. The Bankruptcy Court approves the term sheet raising the Sackler contribution; eight states and D.C. drop objections c-ch11-nine-settlement
  81. The Second Circuit reverses the District Court and reinstates confirmation of the plan c-rel-ca2-decision
  82. The sale of Avrio Health's assets to an Arcadia Consumer Healthcare subsidiary closes c-bus-avrio-sale
  83. Attorneys general announce a $350 million agreement with Publicis Health c-cons-publicis-resolution
  84. The Supreme Court holds in Harrington v. Purdue Pharma L.P. that the code does not authorise nonconsensual releases of claims against non-debtors c-rel-scotus-holding
  85. The Bankruptcy Court grants the creditors' committee sole standing to pursue the estates' claims c-ch11-ucc-standing
  86. Mediators report agreements in principle with all but one Sackler family group, the debtors and creditor groups c-rel-2024-mediation
  87. The District Court affirms the 2024 injunction extensions on the State of Maryland's appeal c-rel-maryland-appeal
  88. McKinsey agrees to a $650 million resolution with a deferred prosecution agreement over charges against its U.S. subsidiary c-cons-mck-2024-resolution c-cons-mck-information c-cons-elling-charge
  89. Purdue's debtors file the Thirteenth Amended Chapter 11 plan after the Supreme Court remand c-plan25-thirteenth-plan
  90. Stipulation dismisses Richard Sackler's Wyoming trust suit and binds him and Lin Gao not to interfere with the settlement c-enf-wyoming-litigation
  91. Bankruptcy Court confirms the Eighteenth Amended plan with opt-in third-party releases c-plan25-confirmation c-plan25-releases
  92. Purdue Pharma L.P. is sentenced to a $3.544 billion criminal fine and $2 billion forfeiture c-plea20-sentence
  93. Plan takes effect: Purdue ceases operations and Knoa Pharma LLC begins operating its business c-plan25-effective c-plan25-knoa-launch
  94. Bankruptcy Court grants the Side B trustees' motion to enforce the settlement against Richard Sackler and Lin Gao c-enf-side-b-motion c-enf-breach-ruling
  95. Florida records cancellation of Purdue Pharma L.P. and withdrawal of Purdue Pharma Inc. c-id-florida-cards
  96. Written ruling finds Richard Sackler and Lin Gao breached the confirmation order, settlement agreement and stipulation c-enf-breach-ruling

Sources 115

  1. src-001 · Court recordPurdue's notice of suggestion of bankruptcy and automatic stay, with the Chapter 11 petition of Purdue Pharma L.P. (Commonwealth of Massachusetts v. Purdue Pharma L.P.) Commonwealth of Massachusetts (Office of the Attorney General) · 16 Sep 2019

    Notice of 16 Sept. 2019; Official Forms 201, 202 and 204; board resolutions Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  2. src-002 · Regulatory recordConsultants' filing in the Utah Division of Consumer Protection case against Purdue Pharma L.P. et al. (DCP Legal File No. CP-2019-005) Utah Department of Commerce, Division of Consumer Protection

    Docket item DK-114, caption and first pages Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  3. src-003 · Court recordMemorandum decision and order of Judge Colleen McMahon vacating the confirmation order, In re Purdue Pharma L.P., S.D.N.Y. 21-cv-7532 (CM) (master case; filed as Document 148 in related case 7:21-cv-07585) Office of the Connecticut Attorney General · 16 Dec 2021

    Decision of 16 Dec. 2021, statement of facts and holdings Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  4. src-004 · Court recordSettlement agreement between the United States and the Named Sacklers, with addenda U.S. Department of Justice · Oct 2020

    Settlement agreement, Addenda A and C Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  5. src-005 · Regulatory recordNew York Attorney General press release on the shutdown of Purdue Pharma and the start of Knoa Pharma Office of the New York State Attorney General · 1 May 2026

    Press release of 1 May 2026 Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  6. src-006 · Regulatory recordState of Delaware news release: Purdue–Sackler $7.4 billion opioid settlement goes into effect State of Delaware (Department of Justice) · 1 May 2026

    News release of 1 May 2026 Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  7. src-007 · Court recordDeclarations of the director defendants, Commonwealth of Massachusetts v. Purdue Pharma L.P., No. 1884-cv-01808(B) Commonwealth of Massachusetts (Office of the Attorney General) · 16 Jul 2019

    Sworn declarations of family and independent directors Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  8. src-008 · Company statementCompany statement source · src-008 identified by category only · Company statement
  9. src-009 · Corporate registryCompanies House officer appointments page: Theresa Elizabeth Sackler Companies House (UK)

    Officer appointments list Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  10. src-010 · Company statementSettlement agreement between Purdue Pharma L.P. and affiliates and Depomed, Inc. (Exhibit 10.10) U.S. Securities and Exchange Commission (EDGAR) · 28 Aug 2018

    Exhibit 10.10, parties, recitals and signature page Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  11. src-011 · Court recordDeclaration of Craig Landau in support of the CEO defendants' motion to dismiss, Commonwealth of Massachusetts v. Purdue Pharma L.P. Commonwealth of Massachusetts (Office of the Attorney General) · 3 Jul 2019

    Sworn declaration Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  12. src-012 · Corporate registryCompanies House officer appointments page: Ilene Sackler Lefcourt Companies House (UK)

    Officer appointments list Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  13. src-013 · Corporate registryCompanies House officer appointments page: Mortimer David Alfons Sackler Companies House (UK)

    Officer appointments list Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  14. src-014 · Court recordCourt record source · src-014 identified by category only · Court record
  15. src-015 · Court recordCourt record source · src-015 identified by category only · Court record
  16. src-016 · Court recordCourt record source · src-016 identified by category only · Court record
  17. src-017 · Corporate registryCompanies House officer appointments page: Richard Stephen Sackler Companies House (UK)

    Officer appointments list Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  18. src-018 · Corporate registryCompanies House officer appointments page: Kathe Anne Sackler Companies House (UK)

    Officer appointments list Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  19. src-019 · Corporate registryCompanies House officer appointments page: David Alex Sackler Companies House (UK)

    Officer appointments list Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  20. src-020 · Court recordCourt record source · src-020 identified by category only · Court record
  21. src-021 · OtherOther source · src-021 identified by category only · Other
  22. src-022 · Corporate registryCompanies House officer appointments page: Jonathan David Sackler Companies House (UK)

    Officer appointments list Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  23. src-023 · Corporate registryCompanies House officer appointments page: Beverly Sackler Companies House (UK)

    Officer appointments list Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  24. src-024 · Company statementStrategic Alliance Agreement between Infinity Pharmaceuticals, Inc. and Purdue Pharmaceutical Products L.P. (Exhibit 10.1) U.S. Securities and Exchange Commission (EDGAR) · 19 Nov 2008

    Exhibit 10.1 and attached press release Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  25. src-025 · Company statementNovelos Therapeutics, Inc. prospectus (Rule 424(b)(3)) U.S. Securities and Exchange Commission (EDGAR) · 2010

    Prospectus: selling stockholders and history of financings Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  26. src-026 · Corporate registryCorporate registry source · src-026 identified by category only · Corporate registry
  27. src-027 · OtherOther source · src-027 identified by category only · Other
  28. src-028 · OtherOther source · src-028 identified by category only · Other
  29. src-029 · OtherOther source · src-029 identified by category only · Other
  30. src-030 · OtherOther source · src-030 identified by category only · Other
  31. src-031 · Regulatory recordCharity Commission register: trustees of The Dr Mortimer and Theresa Sackler Foundation (charity no. 1128926) Charity Commission for England and Wales

    Trustees page Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  32. src-032 · Court recordDeclaration of Mark Timney in support of the CEO defendants' motion to dismiss, Commonwealth of Massachusetts v. Purdue Pharma L.P. Commonwealth of Massachusetts (Office of the Attorney General) · 3 Jul 2019

    Sworn declaration Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  33. src-033 · Court recordDeclaration of John Stewart in support of the CEO defendants' motion to dismiss, Commonwealth of Massachusetts v. Purdue Pharma L.P. Commonwealth of Massachusetts (Office of the Attorney General) · 3 Jul 2019

    Sworn declaration Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  34. src-034 · Regulatory recordHHS-OIG news release: administrative law judge upholds exclusions of responsible corporate officers in the OxyContin case U.S. Department of Health and Human Services, Office of Inspector General · 23 Jan 2009

    News release of 23 Jan. 2009 Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  35. src-035 · Company statementSunEdison, Inc. Form 8-K on the appointment of John S. Dubel as chief executive officer U.S. Securities and Exchange Commission (EDGAR) · 22 Jun 2016

    Form 8-K, Item 5.02 Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  36. src-036 · Regulatory recordWIPO administrative panel decision, Case No. D2010-1811 (OxyContin domain names) WIPO Arbitration and Mediation Center · 4 Dec 2010

    Decision, parties and factual background Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  37. src-037 · OtherMajority staff memorandum, House Committee on Oversight and Reform, on the December 2020 hearing with Purdue and Sackler witnesses U.S. House of Representatives, Committee on Oversight and Reform · 8 Dec 2020

    Memorandum and witness list Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  38. src-038 · Court recordProof of claim of the United States (Department of Justice) in In re Purdue Pharma L.P., with attachment Commonwealth of Massachusetts (Office of the Attorney General) · 30 Jul 2020

    Claim No. 137848, rider and attachment Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  39. src-039 · Court recordCourt record source · src-039 identified by category only · Court record
  40. src-040 · Court recordHarrington, United States Trustee, Region 2 v. Purdue Pharma L.P., No. 23-124, opinion of the Court and dissent Supreme Court of the United States · 27 Jun 2024

    Slip opinion: syllabus, majority opinion, dissent Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  41. src-041 · Court recordInformation, United States v. Purdue Pharma L.P., D.N.J. Criminal No. 20-1028 (MCA) U.S. Department of Justice · 24 Nov 2020

    Information, Counts One to Three and forfeiture allegation Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  42. src-042 · Court recordCourt record source · src-042 identified by category only · Court record
  43. src-043 · Company statementCompany statement source · src-043 identified by category only · Company statement
  44. src-044 · Court recordCourt record source · src-044 identified by category only · Court record
  45. src-045 · Regulatory recordDOJ press release: global resolution of criminal and civil investigations with Purdue Pharma and civil settlement with the Sackler family U.S. Department of Justice · 21 Oct 2020

    Press release of 21 Oct. 2020 Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  46. src-046 · Company statementSettlement agreement between the Purdue companies and Endo Pharmaceuticals (Exhibit 99.1) U.S. Securities and Exchange Commission (EDGAR) · 28 Aug 2006

    Exhibit 99.1, parties and recitals Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  47. src-047 · Court recordCourt record source · src-047 identified by category only · Court record
  48. src-048 · MediaMedia source · src-048 identified by category only · Media
  49. src-049 · MediaMedia source · src-049 identified by category only · Media
  50. src-050 · MediaMedia source · src-050 identified by category only · Media
  51. src-051 · Court recordAmended complaint, State of Connecticut v. Purdue Pharma L.P. et al., No. X07 HHD-CV-19-6105325-S (partially redacted) Office of the Connecticut Attorney General · 6 May 2019

    Amended complaint, parties and allegations Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  52. src-052 · Court recordCourt record source · src-052 identified by category only · Court record
  53. src-053 · Corporate registryCompanies House officer appointments page: Samantha Sophia Sackler Hunt Companies House (UK)

    Officer appointments list Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  54. src-054 · Regulatory recordForm 4 statement of changes in beneficial ownership, Key Technology Inc. (reporting person M3C Holdings LLC) U.S. Securities and Exchange Commission (EDGAR) · 20 Apr 2015

    Form 4 and explanation of responses Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  55. src-055 · Court recordCourt record source · src-055 identified by category only · Court record
  56. src-056 · MediaMedia source · src-056 identified by category only · Media
  57. src-057 · Company statementCompany statement source · src-057 identified by category only · Company statement
  58. src-058 · Court recordCourt record source · src-058 identified by category only · Court record
  59. src-059 · ResearchResearch source · src-059 identified by category only · Research
  60. src-060 · Regulatory recordNew York Attorney General press release: more than $573 million from McKinsey & Company Office of the New York State Attorney General · 4 Feb 2021

    Press release of 4 Feb. 2021 Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  61. src-061 · Court recordComplaint, The People of the State of New York v. McKinsey & Company, Inc. United States, Index No. 400001/2021 Office of the New York State Attorney General · 5 Feb 2021

    Complaint Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  62. src-062 · Regulatory recordNew York Attorney General press release: $350 million from Publicis for its role in the opioid crisis Office of the New York State Attorney General · 1 Feb 2024

    Press release of 1 Feb. 2024 Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  63. src-063 · Company statementCompany statement source · src-063 identified by category only · Company statement
  64. src-064 · MediaMedia source · src-064 identified by category only · Media
  65. src-065 · MediaMedia source · src-065 identified by category only · Media
  66. src-066 · Company statementCompany statement source · src-066 identified by category only · Company statement
  67. src-067 · Court recordInformation against McKinsey & Company, Inc. United States (Attachment 4 to the deferred prosecution agreement) U.S. Department of Justice · 13 Dec 2024

    Information Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  68. src-068 · Regulatory recordDOJ press release: resolution of criminal and civil investigations into McKinsey & Company's work for Purdue U.S. Department of Justice · 13 Dec 2024

    Press release of 13 Dec. 2024 Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  69. src-069 · Corporate registryCompanies House officers page: The Sackler Trust (07022224) Companies House (UK) · 22 Oct 2026

    Company officers list Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  70. src-070 · Corporate registryCompanies House officers page: Tradewhiz Limited (03896720) Companies House (UK)

    Company officers list Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  71. src-071 · Corporate registryCompanies House officer appointments page: Tiercel Services Limited Companies House (UK)

    Officer appointments list Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  72. src-072 · Regulatory recordVillage of Hastings-on-Hudson notice: protest petitions for the Route 9A property withdrawn Village of Hastings-on-Hudson, Board of Trustees · 2005

    Notice Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  73. src-073 · Company statementCelldex Therapeutics, Inc. prospectus (Rule 424(b)(3)) U.S. Securities and Exchange Commission (EDGAR) · Feb 2017

    Prospectus: selling stockholders and Kolltan acquisition Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  74. src-074 · Company statementCompany statement source · src-074 identified by category only · Company statement
  75. src-075 · MediaMedia source · src-075 identified by category only · Media
  76. src-076 · Corporate registryCompanies House filing history: Napp Pharmaceutical Holdings Limited (03486244), page 5 Companies House (UK)

    Filing history Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  77. src-077 · Regulatory recordDOJ press release: opioid manufacturer Purdue Pharma sentenced for fraud and kickback conspiracies U.S. Department of Justice · 28 Apr 2026

    Press release of 28 Apr. 2026 Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  78. src-078 · Court recordCourt record source · src-078 identified by category only · Court record
  79. src-079 · Regulatory recordRhode Island Pollutant Discharge Elimination System draft permit No. RI0023868 for Rhodes Technologies, Coventry (2015) U.S. Environmental Protection Agency (archived snapshot) · 2015

    Draft permit and fact sheet Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  80. src-080 · MediaMedia source · src-080 identified by category only · Media
  81. src-081 · MediaMedia source · src-081 identified by category only · Media
  82. src-082 · MediaMedia source · src-082 identified by category only · Media
  83. src-083 · MediaMedia source · src-083 identified by category only · Media
  84. src-084 · Corporate registryCompanies House officer appointments page: Stuart David Baker Companies House (UK)

    Officer appointments list Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  85. src-085 · MediaMedia source · src-085 identified by category only · Media
  86. src-086 · MediaMedia source · src-086 identified by category only · Media
  87. src-087 · Court recordCourt record source · src-087 identified by category only · Court record
  88. src-088 · MediaMedia source · src-088 identified by category only · Media
  89. src-089 · Corporate registryCompanies House officers page: Napp Pharmaceutical Group Limited (00884285) Companies House (UK)

    Company officers list Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  90. src-090 · MediaMedia source · src-090 identified by category only · Media
  91. src-091 · MediaMedia source · src-091 identified by category only · Media
  92. src-092 · MediaMedia source · src-092 identified by category only · Media
  93. src-093 · MediaMedia source · src-093 identified by category only · Media
  94. src-094 · MediaMedia source · src-094 identified by category only · Media
  95. src-095 · MediaMedia source · src-095 identified by category only · Media
  96. src-096 · Court recordCourt record source · src-096 identified by category only · Court record
  97. src-097 · Court recordCourt record source · src-097 identified by category only · Court record
  98. src-098 · OtherOther source · src-098 identified by category only · Other
  99. src-099 · Company statementJazz Pharmaceuticals plc proxy statement (definitive) U.S. Securities and Exchange Commission (EDGAR) · 29 May 2026

    Director biographies Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  100. src-100 · Company statementWritten testimony of Dr. Craig Landau, CEO of Purdue Pharma L.P., before the House Committee on Oversight and Reform U.S. House of Representatives, Committee on Oversight and Reform · 17 Dec 2020

    Written testimony Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  101. src-101 · Court recordCourt record source · src-101 identified by category only · Court record
  102. src-102 · Corporate registryFlorida Division of Corporations record: Purdue Pharma Inc. (F03000005558) Florida Department of State, Division of Corporations · 28 Feb 2026

    Detail by entity name; officers from the latest annual report Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  103. src-103 · Corporate registryFlorida Division of Corporations record: Purdue Pharma L.P. (B03000000381) Florida Department of State, Division of Corporations

    Detail by entity name Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  104. src-104 · Corporate registryWyoming Secretary of State business entity detail: Cedar Cliff Fiduciary Management Inc. Wyoming Secretary of State · 5 Aug 2026

    Entity detail and annual report history Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  105. src-105 · Court recordCourt record source · src-105 identified by category only · Court record
  106. src-106 · MediaMedia source · src-106 identified by category only · Media
  107. src-107 · MediaMedia source · src-107 identified by category only · Media
  108. src-108 · OtherOther source · src-108 identified by category only · Other
  109. src-109 · MediaMedia source · src-109 identified by category only · Media
  110. src-110 · Corporate registryFlorida filing: application of Purdue Pharma L.P. for authority to transact business and affidavit of capital contributions (2003) Florida Department of State, Division of Corporations · Nov 2003

    Filed application and affidavit Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  111. src-111 · Court recordCourt record source · src-111 identified by category only · Court record
  112. src-112 · Regulatory recordSchedule 13D Amendment No. 4 regarding Amtech Systems, Inc. U.S. Securities and Exchange Commission (EDGAR) · 27 Nov 2018

    Items 2, 5 and 6 Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  113. src-113 · MediaMedia source · src-113 identified by category only · Media
  114. src-114 · Regulatory recordFederal Election Commission committee record: Purdue Pharma Inc. Political Action Committee (C00370643) U.S. Federal Election Commission

    Committee overview and financial summary Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

  115. src-115 · Court recordGovInfo United States Courts opinions record for case 19-23649, Purdue Pharma L.P. U.S. Government Publishing Office (GovInfo)

    Case details and parties Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 22 October 2026.

cite this dossier

DossierTwist, “Purdue Pharma L.P.: owners, OxyContin cases and bankruptcy”, dt.034, 2 November 2026, https://dossiertwist.com/dossiers/purdue-pharma/

Free to read, cite and republish with credit under CC BY 4.0: credit “DossierTwist” and link to the dossier.

Data: JSON, CSV and the network graph.

share

We listen to all sides: responses are shown next to the claims they answer. To send a correction or a reply, write to dossiertwist@proton.me.